BCD 261
Alternative Names: BCD-261Latest Information Update: 24 Feb 2025
At a glance
- Originator Biocad
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 29 Mar 2024 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in Russia (SC) (NCT06715540)